OncoLize
OncoLize develop high performance oncology products for localised and controlled delivery of drugs, making their products much better at eradicating the tumour, with far fewer side-effects. ChemoGel is a unique, thermoresponsive, hydrogel drug delivery platform for the site-specific delivery and sustained release of chemotherapeutics at solid tumour sites. The global pancreatic cancer treatment market is expected to reach $4.2bn in 2025. ChemoGel enables the targeted delivery of chemotherapeutics, at adequate concentration, to the required site of action thereby achieving a high local concentration for prolonged periods and maximising efficacy.
ChemoGel is based on a novel thermoresponsive hydrogel technology developed at RCSI which can be used to deliver multiple chemotherapeutics simultaneously.
ChemoGel aims to offer a new site-specific approach to cancer treatment by delivering drugs directly to the tumour using minimally-invasive, image guided techniques such as by endoscopic ultrasound fine needle injection (EUS-FNI).
Promoters
- Mike de Leeuw, CEO
- Prof. Helena Kelly, CSO/Academic Founder
Current status
- Patent filed
- In vivo proof of concept
- Raised €1.7m seed round
Next steps
- €3.7m Series A